CN100513560C - 用于病毒增殖的方法 - Google Patents

用于病毒增殖的方法 Download PDF

Info

Publication number
CN100513560C
CN100513560C CNB02814421XA CN02814421A CN100513560C CN 100513560 C CN100513560 C CN 100513560C CN B02814421X A CNB02814421X A CN B02814421XA CN 02814421 A CN02814421 A CN 02814421A CN 100513560 C CN100513560 C CN 100513560C
Authority
CN
China
Prior art keywords
virus
poxvirus
temperature
cell
mva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02814421XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1533433A (zh
Inventor
保罗·豪利
卡尔·赫勒
英格马·雷思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100513560(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN1533433A publication Critical patent/CN1533433A/zh
Application granted granted Critical
Publication of CN100513560C publication Critical patent/CN100513560C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CNB02814421XA 2001-07-18 2002-07-02 用于病毒增殖的方法 Expired - Fee Related CN100513560C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101122 2001-07-18
DKPA200101122 2001-07-18
PCT/EP2002/007280 WO2003008533A2 (en) 2001-07-18 2002-07-02 Method for virus propagation

Publications (2)

Publication Number Publication Date
CN1533433A CN1533433A (zh) 2004-09-29
CN100513560C true CN100513560C (zh) 2009-07-15

Family

ID=8160630

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02814421XA Expired - Fee Related CN100513560C (zh) 2001-07-18 2002-07-02 用于病毒增殖的方法

Country Status (19)

Country Link
US (1) US6924137B2 (enExample)
EP (1) EP1412486B1 (enExample)
JP (2) JP4700907B2 (enExample)
KR (1) KR100908377B1 (enExample)
CN (1) CN100513560C (enExample)
AU (1) AU2002314201B2 (enExample)
BR (2) BRPI0211276B1 (enExample)
CA (1) CA2450206C (enExample)
DE (1) DE60223812T2 (enExample)
DK (1) DK1412486T3 (enExample)
EA (1) EA006628B1 (enExample)
HU (1) HUP0400393A3 (enExample)
IL (2) IL158927A0 (enExample)
MX (1) MXPA04000326A (enExample)
NO (1) NO339056B1 (enExample)
NZ (1) NZ529914A (enExample)
PL (1) PL205926B1 (enExample)
UA (1) UA82466C2 (enExample)
WO (1) WO2003008533A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10913063B2 (en) * 2016-07-12 2021-02-09 EMULATE, Inc. Removing bubbles in a microfluidic device
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
SG11201912429RA (en) 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2024241503A1 (en) 2023-03-17 2025-08-14 Albert-Ludwigs-Universität Freiburg Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567147A (en) * 1984-03-28 1986-01-28 Chiba Prefectural Government Attenuated smallpox vaccine strain
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384845A1 (fr) * 1976-08-05 1978-10-20 Anvar Vaccin contre la myxomatose et nouvelle souche virale utilisee
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1997012032A1 (en) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567147A (en) * 1984-03-28 1986-01-28 Chiba Prefectural Government Attenuated smallpox vaccine strain
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Characteristics of an attenuated vaccinia virus strain,LC16m0,and its recombinant virus vaccines. Sugimoto M, et al.Vaccine,Vol.12 No.8. 1994 *
Influence of the incubation temperature on the dynamics of reproduction and plaque formation of three strains of vaccinia virus in cell cultures. Slonim D, et al.Journal of Hygiene, Epidemiology, Microbiology, and Immunology.,Vol.16 No.4. 1972 *

Also Published As

Publication number Publication date
PL366897A1 (en) 2005-02-07
US6924137B2 (en) 2005-08-02
EP1412486B1 (en) 2007-11-28
BRPI0211276B1 (pt) 2018-12-04
JP2011078424A (ja) 2011-04-21
EA006628B1 (ru) 2006-02-24
KR100908377B1 (ko) 2009-07-20
EP1412486A2 (en) 2004-04-28
EA200400195A1 (ru) 2004-06-24
US20040234950A1 (en) 2004-11-25
JP4700907B2 (ja) 2011-06-15
WO2003008533A2 (en) 2003-01-30
CN1533433A (zh) 2004-09-29
BR0211276A (pt) 2004-08-03
HK1066245A1 (zh) 2005-03-18
KR20040018474A (ko) 2004-03-03
HUP0400393A3 (en) 2004-10-28
UA82466C2 (uk) 2008-04-25
DE60223812T2 (de) 2008-11-13
AU2002314201B2 (en) 2006-09-21
NZ529914A (en) 2005-03-24
MXPA04000326A (es) 2005-03-07
NO339056B1 (no) 2016-11-07
NO20040158L (no) 2004-01-13
DK1412486T3 (da) 2008-03-10
JP5154632B2 (ja) 2013-02-27
WO2003008533A3 (en) 2004-01-08
PL205926B1 (pl) 2010-06-30
JP2004535203A (ja) 2004-11-25
CA2450206C (en) 2012-08-21
IL158927A (en) 2009-09-01
CA2450206A1 (en) 2003-01-30
DE60223812D1 (de) 2008-01-10
IL158927A0 (en) 2004-05-12
HUP0400393A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
CN100513560C (zh) 用于病毒增殖的方法
US8329466B2 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
RU2704485C2 (ru) Стабильные жидкие препараты вируса осповакцины
US7445924B2 (en) Modified Vaccinia Ankara virus variant and cultivation method
ES2345820T3 (es) Produccion de poxvirus con estirpes de celulas aviares adherentes o no adherentes.
AU2002314201A1 (en) Method for virus propagation
JP2004535203A5 (enExample)
HK1066245B (en) Method for virus propagation
WO2025120141A1 (en) Downregulation of yield-reducing transgenes expressed by poxvirus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1066245

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1066245

Country of ref document: HK

CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 200101122 20010718 DK

Number: 28

Volume: 25

CI03 Correction of invention patent

Correction item: Priority

Correct: 200101122 20010718 DK

Number: 28

Page: The title page

Volume: 25

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: NONE TO: 200101122;20010718;DK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090715

Termination date: 20190702